Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Do you consider a company's sales trends when choosing among names? We ran a screen to illustrate how to start your own sales analysis.

We began by screening the biotech industry for high-growth stocks, with 5-year projected EPS growth above 15%.

We then screened for stocks with strong sales trends by comparing growth in revenue to growth in inventory over the last year. We screened for stocks with positive sales trends, with faster growth in revenue than inventory over the last year. Since inventory represents the portion of goods not yet sold, faster growth in revenue than inventory is considered an encouraging sign.

To screen for strengthening liquidity, we also only focused on those companies with inventory decreasing as a percentage of current assets.

For an ‪interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.‬

Tool provided by Kapitall (www.kapitall.com).

Do you think these stocks will continue to see strong sales trends? Use this list as a starting point for your own analysis.

List sorted by increase in revenue over the last year.

1. China Biologic Products, Inc. (CBPO): Engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. Market cap at $258.23M, most recent closing price at $9.73. 5-year projected EPS growth at 30.00%. Revenue grew by 37.02% during the most recent quarter ($47.23M vs. $34.47M y/y). Inventory grew by 22.6% during the same time period ($70.58M vs. $57.57M y/y). Inventory, as a percentage of current assets, decreased from 42.99% to 37.76% during the most recent quarter (comparing 3 months ending 03-31-2012 to 3 months ending 03-31-2011).

2. Anika Therapeutics Inc. (ANIK): Develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Market cap at $204.38M, most recent closing price at $14.67. 5-year projected EPS growth at 30.00%. Revenue grew by 22.32% during the most recent quarter ($14.36M vs. $11.74M y/y). Inventory grew by 3.53% during the same time period ($9.08M vs. $8.77M y/y). Inventory, as a percentage of current assets, decreased from 15.94% to 14.2% during the most recent quarter (comparing 3 months ending 03-31-2012 to 3 months ending 03-31-2011).

3. BioMarin Pharmaceutical Inc. (BMRN): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Market cap at $4.72B, most recent closing price at $38.36. 5-year projected EPS growth at 36.00%. Revenue grew by 12.1% during the most recent quarter ($124.02M vs. $110.63M y/y). Inventory grew by 6.96% during the same time period ($120.12M vs. $112.3M y/y). Inventory, as a percentage of current assets, decreased from 21.84% to 17.63% during the most recent quarter (comparing 3 months ending 06-30-2012 to 3 months ending 06-30-2011).

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 3 High-Growth Biotech Stocks With Encouraging Inventory Trends